INS and metabolic syndrome: Considering its dysregulation in various pathologies [55] and given the CB2R involvement in several conditions such as adipose tissue inflammation, insulin sensitivity, and glucose metabolism, to date, the endocannabinoids system has become a promising target for the study of numerous diseases such as metabolic syndrome, obesity, and other lifestyle-related diseases [56,57].